Loading company…
Boston-based biopharmaceutical company developing therapies for neurodegenerative diseases through protein misfolding drug discovery.
Yumanity Therapeutics, Inc., founded in 2014 and headquartered in Boston, US, focuses on drug discovery for protein misfolding diseases such as Alzheimer's and Parkinson's. Richard Peters is CEO. In June 2022 the company merged with Kineta, Inc., and Janssen Vaccines & Prevention B.V. agreed to acquire its assets for USD 26 mn, with completion expected by March 2023. Reported 2023 revenue was USD 5.44 mn, with EBITDA of USD -13.53 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in